Real-World safety check for new bile duct cancer drug
NCT ID NCT06793709
Summary
This study is monitoring the safety of Tasfygo tablets in real-world patients with advanced bile duct cancer that cannot be surgically removed. It includes 60 patients who have a specific genetic change (FGFR2 fusion) and whose cancer worsened after standard chemotherapy. The main goal is to track any side effects or adverse reactions that occur while patients take this already-approved medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
#Eisai Trial Site 1
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.